Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

HTLV-I-associated Myelopathy Clinical Trial

Official title:
Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

Status Completed

Clinical Trial Summary

To determine whether the use of two antiviral agents in combination will be better than placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I

Clinical Trial Description

Randomised, double-blind, placebo-controlled two centre study of zidvoudine plus lamivudine in HAM/TSP 24 patients randomised 1:1 2-4 week lead-in 6 months randomised phase followed by 6 months open-label therapy with active drug Primary endpoint: clinical Secondary endpoints: virological and immunological ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00272480
Study type	Interventional
Source	Imperial College London
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	November 8, 1999
Completion date	July 30, 2002

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00823641` - The HAM Infliximab Study	Phase 2
Terminated	`NCT00519181` - Safety and Efficiency Study of Valproic Acid In HAM/TSP	N/A
Active, not recruiting	`NCT01343355` - Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)	Phase 2/Phase 3